Department of Surgery, Nippon Medical School, Tokyo, Japan.
Ann Surg. 2010 Apr;251(4):620-3. doi: 10.1097/SLA.0b013e3181d48a6a.
To investigate whether maximal sterile barrier precautions (MSBPs) during central venous catheter (CVC) insertion are truly effective in preventing catheter-related bloodstream infections (CRBSIs) in patients in general surgical units.
The reported effectiveness of MSBPs was based on the results of a single-center randomized controlled trial by Raad et al and the majority of the patients (99%) in the study were chemotherapy outpatients.
Between March 14, 2004 and December 28, 2006, the patients scheduled for CVC insertion in surgical units at 9 medical centers in Japan were randomly assigned to either an MSBP group (n = 211) or a standard sterile barrier precaution (SSBP) group (n = 213). This study was registered in the UMIN Clinical Trials Registry (registration ID number: UMIN000001400).
The median (range) duration of catheterization was 14 days (0-92 days) in the MSBP group and 14 days (0-112 days) in the SSBP group. There were 5 cases (2.4%) of CRBSI in the MSBP group and 6 cases (2.8%) in the SSBP group (relative risk, 0.84; 95% confidence interval, 0.26-2.7; P = 0.77). The rate of CRBSIs per 1000 catheter days was 1.5 in the MSBP group and 1.6 in the SSBP group. There were 8 cases (3.8%) of catheter-related infections in the MSBP group and 7 cases (3.3%) in the SSBP group (relative risk, 1.2; 95% confidence interval, 0.43-3.1; P = 0.78). The rate of catheter-related infection per 1000 catheter days was 2.4 in the MSBP group and 1.9 in the SSBP group.
This study is larger in sample size than the one performed by Raad et al and could not demonstrate better prevention of CRBSIs by MSBP compared with SSBP. A large randomized controlled trial or at least a meta-analysis of any other studies in the literature is necessary to reach to a conclusion on this issue.
调查在普通外科病房中,进行最大无菌屏障预防措施(MSBPs)是否能有效预防中心静脉导管(CVC)相关血流感染(CRBSIs)。
MSBPs 的有效性是基于 Raad 等人的一项单中心随机对照试验的结果,并且研究中的大多数患者(99%)为化疗门诊患者。
2004 年 3 月 14 日至 2006 年 12 月 28 日,日本 9 家医疗中心的外科病房中计划进行 CVC 置管的患者被随机分配至 MSBP 组(n = 211)或标准无菌屏障预防(SSBP)组(n = 213)。本研究已在 UMIN 临床试验注册中心注册(注册号:UMIN000001400)。
MSBP 组的置管时间中位数(范围)为 14 天(0-92 天),SSBP 组为 14 天(0-112 天)。MSBP 组有 5 例(2.4%)CRBSI,SSBP 组有 6 例(2.8%)(相对风险,0.84;95%置信区间,0.26-2.7;P = 0.77)。MSBP 组每 1000 导管日的 CRBSI 发生率为 1.5,SSBP 组为 1.6。MSBP 组有 8 例(3.8%)导管相关感染,SSBP 组有 7 例(3.3%)(相对风险,1.2;95%置信区间,0.43-3.1;P = 0.78)。MSBP 组每 1000 导管日的导管相关感染发生率为 2.4,SSBP 组为 1.9。
本研究的样本量大于 Raad 等人的研究,未能证明与 SSBP 相比,MSBP 能更好地预防 CRBSIs。需要进行大规模的随机对照试验,或至少对文献中的其他研究进行荟萃分析,才能对此问题得出结论。